HUMA
NASDAQHumacyte Inc.
News25/Ratings11
News · 26 weeks45-46%
2025-12-142026-06-07
Mix3290d
- SEC Filings11(34%)
- Other9(28%)
- Insider4(13%)
- Offering3(9%)
- Leadership3(9%)
- Earnings2(6%)
Latest news
25 items- SECHumacyte Inc. filed SEC Form 8-K: Other Events8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June - DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research providing evidence of self-repair of
- INSIDERDirector Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERDirector Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERCFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERChief Medical Officer Parikh Shamik J sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 272,713 units (SEC Form 4) (for withholding tax)4 - Humacyte, Inc. (0001818382) (Issuer)
- PRHumacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals - DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA). The SAC SING (Surgical Implant – Next Generation) contract makes Symvess more e
- SECSEC Form S-8 filed by Humacyte Inc.S-8 - Humacyte, Inc. (0001818382) (Filer)
- SECSEC Form 10-Q filed by Humacyte Inc.10-Q - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces First Quarter 2026 Financial Results and Provides Business Update- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair - - U.S. Department of Defense funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access - -Confe
- PRHumacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte's corporate leadership team as clinical adoption of Symvess® ramps up and pipeline indications move toward planned approval - DURHAM, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Todd E. Rasmussen, M.D., has joined the company as Chief Surgical Officer. In this role, Dr. Rasmusse
- SECHumacyte Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 First Quarter Financial Results and Corporate UpdateDateMay 13, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)13760221 (Conference ID)Call
- SECSEC Form DEF 14A filed by Humacyte Inc.DEF 14A - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, April 28, 2026 at 8:00 AM ET featuring Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center, Salisbury VA Medical Center), and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS (Brigham & Women's Hospital, Center for Surgery and Public Health, Harvard Medical School), who will join company management to discuss the unmet need and current treatment landscape fo
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
- SECHumacyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S. distribution of Symvess remain unchanged DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius
- PRHumacyte Appoints Jim Mercadante as Chief Commercial Officer– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as Symvess® (acellular tissue engineered vessel-tyod) market launch accelerates and pipeline advances toward planned BLA filing in dialysis – DURHAM, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the appointment of Jim Merc
- PRHumacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its Marketing Authorization Application (MAA) seeking approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair has been accepted by the Israel Ministry of Health. The Ministry of Health has set a 180-working-day review period for the MAA
- SECSEC Form PRE 14A filed by Humacyte Inc.PRE 14A - Humacyte, Inc. (0001818382) (Filer)
- SECSEC Form 10-K filed by Humacyte Inc.10-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a c
- PRHumacyte Appoints Rick McElheny as Senior Vice President of Business Development- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. - - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
HUMA FAQ
6 questionsWhere does HUMA stock trade?
Humacyte Inc. (HUMA) is listed on NASDAQ.What sector and industry is HUMA in?
Humacyte Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Humacyte Inc. go public?
Humacyte Inc. (HUMA) completed its IPO in 2020.What are analysts saying about HUMA?
Humacyte Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $350.00 price target on 2025-08-27. Recent price targets range from $350.00 to $1700.00.What companies are similar to HUMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare HUMA side-by-side with any of them on Quantisnow.How can I track HUMA on Quantisnow?
Quantisnow aggregates Humacyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HUMA to receive live email and push alerts on every new disclosure.